Related Experiment Videos
Anaphylatoxins in dilated cardiomyopathy
M Samsonov1, E Nassonov, V Masenko
1Department of Congestive Heart Failure and Laboratory of Clinical Immunology, Institute of Cardiology, Cardiology Research Center, Moscow, Russia.
Insights
Elevated C3a levels, a marker of complement system activation, are linked to thromboembolic complications in dilated cardiomyopathy patients. This suggests anaphylatoxins may contribute to clot formation in this condition.
Area of Science:
- Cardiology
- Immunology
- Biochemistry
Background:
- Dilated cardiomyopathy (DCMP) is associated with an increased risk of thromboembolic events.
- The role of the complement system, particularly anaphylatoxins like C3a and C5a, in DCMP pathogenesis is not fully understood.
Purpose of the Study:
- To investigate the relationship between complement system activation and thromboembolic complications in patients with dilated cardiomyopathy.
- To compare C3a and C5a levels in DCMP patients with those in hypertrophic cardiomyopathy (HCMP) and healthy controls.
Main Methods:
- Plasma concentrations of C3a and C5a were measured using radioimmunoassay.
- Study included 23 DCMP patients, 9 HCMP patients, and 11 healthy volunteers.
Main Results:
- Mean C3a concentration was significantly higher in DCMP patients compared to HCMP patients and healthy controls (P < 0.001).
- No significant correlations were found for C5a concentrations.
- DCMP patients with thromboembolic complications exhibited significantly higher mean C3a levels than those without (P < 0.001).
Conclusions:
- Anaphylatoxins, specifically C3a, may play a role in the development of thromboembolic complications in dilated cardiomyopathy.
- These findings highlight a potential therapeutic target for preventing clot formation in DCMP.
Objects:
The aim of the study was to investigate the possible relationship between activation of complement system and thromboembolic complications in dilated cardiomyopathy (DCMP).
Methods:
The plasma C3a and C5a concentrations were determined by radioimmunoassay measurement (Amersham International, UK) in 23 patients with DCMP, 9 with hypertrophic cardiomyopathy (HCMP) and 11 healthy volunteers.
Results:
The mean C3a concentration was significantly higher in DCMP patients (572 +/- 55 ng ml-1) compared with hypertrophic cardiomyopathy (344 +/- 30 ng ml-1) and with healthy controls (294 +/- 43 ng ml-1) (P < 0.001). There were no significant correlations for C5a concentrations in this group. Mean C3a concentration in DCMP patients with thromboembolic complications (736 +/- 95 ng ml-1) was also significantly higher compared with DCMP patients without these complications (344 +/- 14 ng ml-1) (P < 0.001).
Conclusions:
We conclude that anaphylatoxins may play a role in the pathogenesis of thromboembolic complications.